FDA Sets August Deadline to Review Moderna’s Flu Vaccine After Reversal
The U.S. Food and Drug Administration agreed to review Moderna's mRNA flu vaccine after initially rejecting the application last week, with a decision due by August. Moderna announced the reversal on Feb. 18, following discussions that addressed concerns over the study's design.